This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3
by Zacks Equity Research
Alkermes (ALKS) beats estimates in the third quarter of 2019. Its proprietary products, especially Aristada, drive revenues.
Medicines Company's Inclisiran Succeeds in Pivotal Studies
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent
by Zacks Equity Research
Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.
Alnylam Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.
Alnylam Begins Phase III Study on Onpattro for New Indication
by Zacks Equity Research
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
What Makes Alnylam (ALNY) a New Buy Stock
by Zacks Equity Research
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is Alnylam (ALNY) Up 2.3% Since Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medicines Company's Inclisiran Succeeds in Pivotal Study
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in a pivotal study. Shares up.
Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe
by Zacks Equity Research
Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
by Zacks Equity Research
Key highlights of the past week include collaborations, and other regulatory and pipeline news.
Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs wider-than-expected loss and misses sales estimates in the second quarter of 2019.
Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid
by Zacks Equity Research
Regeneron (REGN) tops on Q2 earnings and sales in the second quarter on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -1.10% and -5.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) posts wider-than-expected loss, while sales beat estimates in the second quarter of 2019.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.
Amgen (AMGN) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Amgen (AMGN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
by Zacks Equity Research
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.
Horizon's NDA for Procysbi New Dosage Form Accepted by FDA
by Zacks Equity Research
The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.
Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
by Zacks Equity Research
Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.
Adverum (ADVM) Jumps: Stock Rises 5.1%
by Zacks Equity Research
Adverum (ADVM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
by Zacks Equity Research
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
by Zacks Equity Research
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).